Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · colon-landscapes@1

SRR12475115

—

bd198a93-47a4-5f89-830b-d9885fc0a226

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.390
  • PROTEIN_SECRETION+0.360
  • INTERFERON_GAMMA_RESPONSE+0.350
  • ANDROGEN_RESPONSE+0.280
  • HEME_METABOLISM+0.270
  • INTERFERON_ALPHA_RESPONSE+0.270
  • INFLAMMATORY_RESPONSE+0.260
  • BILE_ACID_METABOLISM+0.240
  • COMPLEMENT+0.240
  • UV_RESPONSE_DN+0.230

Top 10 suppressed

  • MYC_TARGETS_V2-0.670
  • E2F_TARGETS-0.590
  • MYC_TARGETS_V1-0.580
  • DNA_REPAIR-0.500
  • G2M_CHECKPOINT-0.500
  • MTORC1_SIGNALING-0.350
  • WNT_BETA_CATENIN_SIGNALING-0.350
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
  • UNFOLDED_PROTEIN_RESPONSE-0.340
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR12475112
colon-landscapes@1
——0.968
2SRR17866825
colon-landscapes@1
——0.881
3SRR12475121
colon-landscapes@1
——0.869
4SRR12475139
colon-landscapes@1
——0.860
5TCGA-55-7725-01A-11R-2170-07
lung-landscapes@6
—cohortMD20.842
6SJEPD031138_D2.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.838
7TCGA-05-4410-01A-21R-1858-07
lung-landscapes@6
—cohortA10.836
8TCGA-97-7552-01A-11R-2039-07
lung-landscapes@6
—cohortA10.829
9BS_2SFTWNVE
medullo-epn-umap@date-based
MedMedulloblastoma0.823
10SRR657151
brain-umap@2
GTEX—0.822

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.390Idelalisib— uncovered
PROTEIN_SECRETION0.360Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.350Idelalisib— uncovered
ANDROGEN_RESPONSE0.280Inavolisib— uncovered
HEME_METABOLISM0.270Temsirolimus— uncovered
INTERFERON_ALPHA_RESPONSE0.270Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
BILE_ACID_METABOLISM0.240Inavolisib— uncovered
COMPLEMENT0.240Inavolisib— uncovered
UV_RESPONSE_DN0.230Inavolisib— uncovered
KRAS_SIGNALING_UP0.210Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
FATTY_ACID_METABOLISM0.140Inavolisib— uncovered
APICAL_SURFACE0.130Temsirolimus— uncovered
XENOBIOTIC_METABOLISM0.130Inavolisib— uncovered
PANCREAS_BETA_CELLS0.120Cobimetinib— uncovered
IL2_STAT5_SIGNALING0.110Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
KRAS_SIGNALING_DN0.100Remibrutinib— uncovered
TGF_BETA_SIGNALING0.070Inavolisib— uncovered